Corpus Intelligence IC Memo — MERCY HOSPITAL 2026-04-26 09:54 UTC
IC Memo — MERCY HOSPITAL
Investment Committee Memorandum | CA | 229 beds | Grade C | EBITDA uplift $27.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

MERCY HOSPITAL

CCN 050295 | KERN, CA | 229 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

MERCY HOSPITAL is a 229-bed suburban community hospital in KERN, CA with $371.2M in net patient revenue and a -0.7% operating margin. The hospital serves a payer mix of 22.0% Medicare, 6.1% Medicaid, and 71.9% commercial.

Thesis: Undervalued. Our ML models identify $27.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -0.7% to 6.7% (+736bps).

Net Revenue HCRIS$371.2M
Current EBITDA COMPUTED$-2.6M
Operating Margin COMPUTED-0.7%
Occupancy HCRIS54.4%
Revenue / Bed COMPUTED$1.6M
Net-to-Gross HCRIS24.3%
Distress Probability ML46.6%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
199
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -0.7% places it above the state median. Among 199 size-comparable peers (114-458 beds), the median margin is -4.0%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (114-458), prioritizing same-state peers. 199 hospitals in the comp set.

HospitalStateBedsRevenueMargin
MERCY HOSPITAL (Target)CA229$371.2M-0.7%
RONALD REAGAN UCLACA446$2.62B-6.8%
LUCILE PACKARD CHILDRENS HOSPICA394$2.39B-0.8%
UCI MEDICAL CENTERCA397$1.90B-2.5%
CITY OF HOPE NATIONAL MEDICAL CA217$1.83B-10.7%
RADY CHILDRENS HOSPITAL - SAN CA401$1.82B14.8%
HARBOR-UCLA MEDICAL CENTERCA369$1.54B-6.4%
EL CAMINO HOSPITALCA388$1.34B11.7%
CHILDRENS HOSPITAL OF ORANGE CCA334$1.31B0.7%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $27.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$7.8M+210bp18mo
Cost to Collect4.5%2.5%$7.4M+200bp12mo
Denial Rate Reduction12.0%6.5%$7.4M+198bp12mo
A/R Days Reduction5200.0%3800.0%$4.5M+122bp9mo
Clean Claim Rate88.0%96.0%$238K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$7.8M
Cost to Collect
$7.4M
Denial Rate Reduction
$7.4M
A/R Days Reduction
$4.5M
Clean Claim Rate
$238K
Total EBITDA Uplift$27.3M
Current EBITDA$-2.6M
+ RCM Uplift+$27.3M
Pro Forma EBITDA$24.7M
Current Margin-0.7%
Pro Forma Margin6.7%
WC Released (1x)$14.2M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-4.0M$256.3M0.00x-100.0%
Base (11x exit)10.0x11.0x$-4.0M$280.6M0.00x-100.0%
Bull Case9.0x11.0x$-3.6M$369.5M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-3.6M$402.0M0.00x-100.0%
Bear Case11.0x10.0x$-4.4M$120.9M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-4.4M$131.6M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 199 hospitals with 114-458 beds
  • Same-state prioritization (n=200)
  • Comp margins: P25=-16.7% / P50=-4.0% / P75=4.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.